| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -3,605,374 |
| Amortization and depreciation | 261,679 |
| Amortization of deferred issuance costs | 192,647 |
| Stock-based compensation | 1,264,608 |
| Fair value change in warrant liability | -784,670 |
| Debt and equity facility costs reclassified to financing activities | 141,416 |
| Non-cash lease expense | 111,613 |
| Valuation adjustments for excess or obsolete inventory | 10,000 |
| Accounts receivable | 1,088,169 |
| Inventory | -398,348 |
| Prepaid expenses | -75,089 |
| Accounts payable | 239,983 |
| Accrued expenses, operating lease and other liabilities | -54,442 |
| Net cash used in operating activities | -2,837,272 |
| Purchases of property and equipment | 81,742 |
| Net cash used in investing activities | -81,742 |
| Proceeds from issuance of common stock attributed to non-private placement equity offerings | 9,614,037 |
| Issuance costs attributed to common stock and warrants issued in private placement | 185,903 |
| Issuance costs related to non-private placement equity offerings | 1,045,971 |
| Deferred issuance costs in connection with debt facility | 297,942 |
| Exercise of warrants | 69,750 |
| Share repurchases for the payment of employee taxes | 124,617 |
| Net cash provided by financing activities | 8,029,354 |
| Net increase (decrease) in cash and cash equivalents | 5,110,340 |
| Cash and cash equivalents at beginning of period | 1,460,042 |
| Cash and cash equivalents at end of period | 6,570,382 |
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)